First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older IMAAVY delivered rapid and substantial reduction in immunoglobulin ...

Johnson & Johnson (NYSE:JNJ) today announced results from the first clinical study of its investigational Ottava surgical ...

Johnson & Johnson's Ottava robotic system completes its first clinical study in bariatric surgery, meeting safety endpoints ...

Johnson & Johnson (NYSE:JNJ) is one of the most undervalued NYSE stocks to buy now. On July 8, Johnson & Johnson announced the submission of a supplemental New Drug Application/sNDA to the US FDA for ...

Currently no FDA-approved therapies are available for wAIHA, a rare, heterogeneous, life-threatening disease in which pathogenic immunoglobulin (IgG) autoantibodies attach to and destroy red blood ...

Bayer received an FDA Untitled Letter this week for its prostate cancer drug Nubeqa, shortly after it launched a lawsuit ...

・Icotyde was jointly discovered by Protagonist and Johnson & Johnson but it will now be commercialized by Johnson & Johnson alone under a license and collaboration agreement established in 2017. ・H.C.

New Brunswick-based Johnson & Johnson has secured U.S. Food and Drug Administration approval for its once-daily plaque psoriasis pill. As the first oral option greenlit by regulators, Icotyde offers a ...

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced ...

Treatment with Akeega plus prednisone and androgen deprivation therapy (ADT) significantly reduced the risk of radiographic progression or death by 54% compared to placebo/abiraterone acetate plus ...

Drug-making giant Johnson & Johnson will officially start marketing four of its medications on the Trump administration's ...